刘剑英+曲川娜

[摘要] 目的 探讨对肾性贫血患者行左卡尼汀+促红细胞生成素联合治疗的临床效果。 方法 将2015年6月~2016年6月我院收治的84例肾性贫血患者作为研究对象,根据数字随机表法分为联合组和单一组,各42例。单一组行促红细胞生成素治疗,联合组则行促红细胞生成素+左卡尼汀联合治疗,观察并比较两组治疗效果、血液相关指标以及不良反应发生率。 结果 联合组治疗有效率(92.86%)显著高于单一组(73.81%),联合组不良反应发生几率(11.90%)显著低于单一组(33.33%),联合组血红蛋白(Hb)以及血细胞比容(Hct)均高于单一组,差异均有统计学意义(P<0.05)。 结论 对肾性贫血患者行促红细胞生成素+左卡尼汀联合治疗,能够在一定程度上降低不良反应的发生率,且能够有效改善患者的贫血症状,获取较为理想的治疗效果。
[关键词] 左卡尼汀;促红细胞生成素;肾性贫血患者;血液指标
[中图分类号] R556 [文献标识码] B [文章编号] 1673-9701(2017)08-0119-03
[Abstract] Objective To investigate the clinical effect of L-carnitine combined with erythropoietin in patients with renal anemia. Methods A total of 84 patients with renal anemia treated in our hospital from June 2015 to June 2016 were enrolled and divided into combination group and single group according to the random number table method,with 42 cases in each group. The single group was given erythropoietin treatment,and the combination group was treated with erythropoietin and L-carnitine. The treatment effect, blood related indices and the rate of adverse reactions between the two groups were observed and compared. Results The effective rate was 92.86% in the combination group,significantly higher than that in the single group (73.81%). The incidence of adverse reactions was 11.90% in the combination group, significantly lower than that in the single group (33.33%). The hemoglobin (Hb) and hematocrit (Hct) in the combination group were higher than those of the single group. the differences were statistically significant for all(P<0.05). Conclusion The combination treatment of erythropoietin and levocarnitine in patients with renal anemia can reduce the risk of adverse reactions to a certain extent. At the same time, the combination treatment can effectively improve the anemia of patients and obtain the ideal therapeutic effect.
[Key words] L-carnitine;Erythropoietin;Patients with renal anemia;Blood indicators
腎性贫血是血液透析患者最为常见的一种临床病症,肾性贫血主要是由于患者体内促红细胞生成素以及细胞寿命减少等原因所造成的贫血病症,是血液透析患者最为常见的一种临床症状,将会严重影响患者的身体健康和生活质量[1-2]。目前,临床上通常采取重组细胞生成素治疗的方式,但是对于部分患者的治疗效果并不显著[3-5]。经过临床研究表明,经促红细胞生成素治疗效果并不显著的患者而言,主要是由于患者长时间接受透析治疗导致体内缺乏左卡尼汀,因此,本研究通过使用促红细胞生成素+左卡尼汀联合治疗,能够在一定程度上增加患者对于促红细胞生成素的反应程度,治疗效果十分显著[6-7]。
1资料与方法
1.1一般资料……p>